Results 121 to 130 of about 7,548 (263)

Review of: "[Perspective] Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Early Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression" [PDF]

, 2023
Alireza Mirzaee
openalex   +3 more sources

Insulin degludec/insulin aspart (IDegAsp) treatment on glycemic control and weight in patients with insulin experienced uncontrolled type 2 diabetes mellitus: A retrospective observational study

Endocrine Regulations
Objective. In this retrospective observational study, we aimed to evaluate the impact of insulin degludec/insulin aspart (IDegAsp) treatment on glycemic status, metabolic parameters, and weight/body mass index (BMI) change at a single tertiary diabetes ...
Cakmak Ramazan, Caklili Ozge Telci, Kapar Caner, Catma Yunus, Bayramlar Osman Faruk, Calikoglu Fulya, Karsidag Kubilay, Dinccag Nevin   +7 more
doaj   +1 more source

Insulin Degludec [PDF]

, 2020
openaire   +1 more source

Prediction of nocturnal hypoglycemia unawareness by fasting glucose levels or post-breakfast glucose fluctuations in patients with type 1 diabetes receiving insulin degludec: A pilot study

, 2017
Hiroshi Takahashi, Rimei Nishimura, Yoshiko Onda, Kiyotaka Ando, Daisuke Tsujino, Kazunori Utsunomiya   +5 more
openalex   +2 more sources

Decision letter for "Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomised, controlled, open‐label, cross‐over trial"

, 2021

openalex   +1 more source

Oral agent offers relief from generalized hyperhidrosis [PDF]

, 2017
Hyperhidrosis is a common, self-limiting problem affecting 2% to 3% of the population in the United States. Patients may complain of localized sweating of the hands, feet, face, or underarms or more systemic, generalized sweating in multiple locations ...
Jarrett, Jennie B., Moss, David, Mounsey, Anne   +2 more
core  

Concentrated insulins: the new basal insulins

Therapeutics and Clinical Risk Management, 2016
Elizabeth M Lamos,1 Lisa M Younk,2 Stephen N Davis3 1Division of Endocrinology, Diabetes and Nutrition, 2Department of Medicine, University of Maryland School of Medicine, 3Department of Medicine, University of Maryland Medical Center, Baltimore, MD ...
Lamos EM, Younk LM, Davis SN
doaj  

Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes

, 2021
Rodolfo J. Galindo, Francisco J. Pasquel, Priyathama Vellanki, Radica Z. Alicic, David W. Lam, Maya Fayfman, Alexandra L. Migdal, Georgia M. Davis, Saumeth Cardona, Maria A. Urrutia, M. Citlalli Perez‐Guzman, K. Walkiria Zamudio-Coronado, Limin Peng, Katherine R. Tuttle, Guillermo E. Umpierrez   +14 more
openalex   +2 more sources

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide

Therapeutics and Clinical Risk Management, 2016
Molly G Minze,1 Lisa M Chastain2 1School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, 2Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA Abstract: The global burden
Minze MG, Chastain LM
doaj  

Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis

Diabetes, Metabolic Syndrome and Obesity
Ruiqing Dong,1,* Lifan Gu,2,* Heping Li,1 Yuanna Hu,3 Hui Liu,4 Xuna Kou,1 Yukun Zhao,1 Meng Zhao,1 Bingyin Shi,1 Hui Guo,1 Wei Qiang1 1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University,
Dong R, Gu L, Li H, Hu Y, Liu H, Kou X, Zhao Y, Zhao M, Shi B, Guo H, Qiang W   +10 more
doaj